Immunomedics Inc. (NASDAQ:IMMU) belonging to the Medical sector has surged 0% and closed its last trading session at $2.5.
The company is expected to report its next EPS on Nov 02 AMC. Currently, the stock has a 1 Year Price Target of $5.5.
The consensus recommendation, according to Zacks Investment research, is 2. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 2 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2 and 2 respectively.
Immunomedics Inc. on 9/30/2016 reported its EPS as $-0.17 with the analysts projecting the EPS of the stock as $-0.11. The company beat the analyst EPS Estimate with the difference of $-0.06. This shows a surprise factor of -54.5%.
Many analysts have provided their estimated foresights on Immunomedics Inc. Earnings, with 1 analysts believing the company would generate an Average Estimate of $-0.12. Whereas they predicted High and Low Earnings Estimate as $-0.12 and $-0.12 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.16.
Analysts are also projecting an Average Revenue Estimate for Immunomedics Inc. as $3.1 Million in the Current Quarter. This estimate is provided by 2 analysts. The High Revenue estimate is predicted as 5.5 Million, while the Low Revenue Estimate prediction stands at 700 Million. The company’s last year sales total was 731 Million.
The Company got Downgrade by Wells Fargo on 21-Jun-16 from Outperform to Market Perform.
7 Insider Sales transactions were made totaling 586617 shares traded.
1 analysts projected Price Targets for Immunomedics Inc.. The analysts believe that the company stock price could grow as high as $5.5. The Low Price target projection by analysts is $5.5 and the Mean Price Target is $5.5.
Immunomedics Inc. (NASDAQ:IMMU) has the market capitalization of $242.73 Million. The company rocked its 52-Week High of $5.44 on Jun 2, 2016 and touched its 52-Week Low of $1.61 on Feb 3, 2016. The stock has Return on Assets (ROA) of -79.2 percent. Return on Equity (ROE) stands at 156.7% and Return on Investment (ROI) of -132.9 percent.
The stock is currently showing YTD performance of -18.57 Percent. The company has Beta Value of 1.36 and ATR value of 0.21. The Weekly and Monthly Volatility stands at 5.38% and 6.52%.
Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, the company have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. They have recently licensed its lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide.